Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

XTL6001

Phase 1Small molecule

SShanghai Xitaili Biomedicine Technology co., Ltd.

XTL6001 is one of 6 small molecule programs targeting Obese. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

5

Competitors

Pipeline

Status by Indication[3][1]

Indication

ObeseRecruiting

ObesePhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Obese

#DrugCompanyPhaseTrials

Mounjaro

Ozempic

HRS-5817

FFujian Shengdi Pharmaceutical Co., Ltd.

XTL6001

SShanghai Xitaili Biomedicine Technology co., Ltd.

Urine Analysis

OOhio State University

Cortrosyn

UUniversity of Virginia

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Obese1 trial

Phase I Study of XTL6001 Injection in Healthy and Obese Subjects

Recruiting·SShanghai Xitaili Biomedicine Technology co., Ltd.·Phase 1·NCT07205432·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for XTL6001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XTL6001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XTL6001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Xitaili Biomedicine Technology co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShanghai Xitaili Biomedicine Technology co., Ltd.

Related News